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Pathogenic Bi-allelic Mutations in NDUFAF8 Cause
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Leigh syndrome is one of the most common neurological phenotypes observed in pediatric mitochondrial disease presentations. It is
characterized by symmetrical lesions found on neuroimaging in the basal ganglia, thalamus, and brainstem and by a loss of motor skills
and delayed developmental milestones. Genetic diagnosis of Leigh syndrome is complicated on account of the vast genetic heterogene-
ity with >75 candidate disease-associated genes having been reported to date. Candidate genes are still emerging, being identified when
‘‘omics’’ tools (genomics, proteomics, and transcriptomics) are applied to manipulated cell lines and cohorts of clinically characterized
individuals who lack a genetic diagnosis. NDUFAF8 is one such protein; it has been found to interact with the well-characterized com-
plex I (CI) assembly factor NDUFAF5 in a large-scale protein-protein interaction screen. Diagnostic next-generation sequencing has iden-
tified three unrelated pediatric subjects, each with a clinical diagnosis of Leigh syndrome, who harbor bi-allelic pathogenic variants in
NDUFAF8. These variants include a recurrent splicing variant that was initially overlooked due to its deep-intronic location. Subject fi-
broblasts were found to express a complex I deficiency, and lentiviral transduction with wild-typeNDUFAF8-cDNA ameliorated both the
assembly defect and the biochemical deficiency. Complexome profiling of subject fibroblasts demonstrated a complex I assembly defect,
and the stalled assembly intermediates corroborate the role of NDUFAF8 in early complex I assembly. This report serves to expand the
genetic heterogeneity associated with Leigh syndrome and to validate the clinical utility of orphan protein characterization. We also
highlight the importance of evaluating intronic sequence when a single, definitively pathogenic variant is identified during diagnostic
testing.Leigh syndrome (MIM: 256000) is one of the most com-
mon neurological phenotypes observed in pediatric mito-
chondrial disease presentations, with an estimated inci-
dence of one per 40,000 births.1 Clinical diagnosis is
supported by characteristic neuroimaging findings, with
symmetrical lesions in the basal ganglia, thalamus, and
brainstem, and is associated with a loss of acquired cogni-
tive, visual, and motor skills. Onset is typically in infancy
or early childhood, though adult-onset Leigh syndrome
is reported.2,3 Although it is phenotypically well defined,
its vast genetic heterogeneity, with >75 disease-associated
genes having been reported to date, makes identification of
the genetic defect challenging.4 Causative pathogenic var-
iants have been identified in both the nuclear genome and
the mitochondrial genome (mtDNA), and these variants
affect various aspects of mitochondrial function including
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SURF1 [MIM: 185620]6), Krebs cycle components (e.g.,
PDHA1 [MIM: 300502]7), mitochondrial protein transla-
tion (e.g.,MTFMT [MIM 611766]8), and valine metabolism
(e.g., ECHS1 [MIM 602292]9).
Evolving from the 100,000 Genomes Project in the UK,
the newly established National Health Service (NHS)
Genomic Medicine Service promises to revolutionize
the genetic diagnosis of heterogeneous conditions such
as Leigh syndrome through clinical whole-genome
sequencing,10 with similar programs occurring elsewhere
including the Bavarian Genome Project in Germany and
at the Victorian Clinical Genetics Services (VCGS) in
Melbourne, Australia. For many affected individuals
though, the success of the NHS Genomic Medicine Service
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of emerging ‘‘omics’’ tools—including but not limited to
genomics, proteomics, and transcriptomics—to cohorts
of clinically characterized individuals who lack a genetic
diagnosis continues to identify novel candidate genes for
Leigh syndrome, including TIMMDC1 (MIM: 615534),
which was found through the use of transcriptomics,11
and NDUFAF8 (MIM: 618461), which was found through
mass spectrometry-based proteomic analyses.12 NDUFAF8,
previously known as the orphan protein C17orf89, was
highlighted as a potential complex I assembly factor based
on its strong protein-protein interaction with the well-
characterized complex I assembly factor NDUFAF5 (MIM:
612360).12 RNAi knockdown of NDUFAF8 expression
in HEK293 cells caused a dramatic reduction in both
NDUFAF5 protein levels and complex I activity, providing
further compelling evidence of an interaction.12 We previ-
ously identified a severe reduction in NDUFAF8 (C17orf89)
expression in an unresolved case of complex I deficiency,12
but failed to identify any potential underlying pathogenic
variants. Here, inclusion of this candidate gene in our mo-
lecular genetic diagnostic pipeline and collaboration with
other diagnostic referral centers has led to the identifica-
tion of three unrelated pediatric cases, each with a clinical
diagnosis of Leigh syndrome and harboring bi-allelic vari-
ants in NDUFAF8. These variants included a recurrent
splicing variant that was initially overlooked due to its
deep-intronic location. This report serves to expand the ge-
netic heterogeneity associated with Leigh syndrome and
validates the clinical utility of orphan protein characteriza-
tion; we also highlight the importance of evaluating in-
tronic sequence when a single, definitively pathogenic
variant is identified during diagnostic testing.
Subject 1 was the first child of non-consanguineous
white, British parents, born at term after an uncomplicated
pregnancy (birthweight 3.05Kg, ninth centile). He was
initially breastfed and thought to be well until, at 3months
of age, he developed infantile spasms with a hypsarryth-
mic electroencephalogram (EEG) and was commenced on
steroid (prednisolone) treatment. He was admitted at
4 months of age with a rhinoviral infection requiring opti-
flow respiratory support. Intussusception was suspected
on account of his inconsolable crying, prompting transfer
to the regional tertiary center. On arrival, he was found
to have a metabolic acidosis with a maximal lactate of
15 mmol/L; intussusception was excluded and he devel-
oped apnoeic episodes requiring invasive ventilation.
Brain MRI (Figure 1) obtained at 5 months of age re-
vealed bilateral symmetrical signal changes in the globi
pallidi, thalami, brainstem, and optic radiations. In addi-
tion, there was evidence of bilateral frontal polymicrogyria
and gray matter heterotopia (not shown), corpus callosal
dysgenesis (Figure 1A), bilateral periventricular cysts, and
absent septum pellucidum (Figure 1B). These MRI changes
are consistent with a clinical diagnosis of Leigh syndrome,
and involvement of the brainstem is likely to underlie his
disrupted respiratory drive. Clinically, he was noted to
have optic atrophy with pale discs and was generally hypo-The Ametonic. He had elevated blood lactate (3.0–6.0 mmol/L;
normal range, < 2 mmol/L) while urinary organic acids
and acylcarnitine profiles were unremarkable. Subject 1
was discharged 2 weeks after admission; he remained
generally hypotonic with increased tone in his lower limbs
and was fed through a neurogastric (NG) tube. He has
made steady albeit slow progress since; currently age 2
years, he is able to roll from front to back, can vocalise
five to 10 words, is fully orally fed, and has visual impair-
ment. He continues to have regular fleeting seizures but
does not require regular anti-epileptic medication. His
electrocardiogram (ECG) and echocardiogram were both
normal, and he has good sustained growth on the 25th cen-
tile for weight and height.
Subject 2 was born to unrelated white, American parents
via caesarean section at 35 weeks following a pregnancy
complicated by intrauterine growth restriction (birth-
weight 1.38 kg, <0.4th centile). Prenatal ultrasound indi-
cated prominent brain ventricles, possible left dysplastic
kidney, and reversed end diastolic flow. A head ultrasound
and brain MRI at birth, obtained due to severe intrauterine
growth restriction (IUGR), showed large areas of bilateral
periventricular cystic encephalomalacia with a thin corpus
callosum and no acute hemorrhage. No abnormalities were
noted in urine cytomegalovirus (CMV) and serum IgM
levels. He spent 4 weeks in neonatal intensive care,
receiving tube feeds, before discharge. He developed in-
fantile spasms at 9 months of age, and an EEG revealed
modified hypsarrhythmia. Small optic nerves and
nystagmus were noted during ophthalmologic review.
Delayed motor development was evident (rolling over at
6 months, sitting at 13–14 months, and pulled-to-stand
at 15 months) at this time, but no regression was evident.
By 2 years of age, he was still neither crawling nor standing
independently, and he had no speech. A viral illness at 2
years, 9 months of age caused a developmental regression,
although some skills were subsequently regained. Brain
MRI (Figure 1) obtained at 2 years, 9 months of age demon-
strated signal abnormality in the dorsal brainstem, corpus
callosum dysgenesis (Figure 1C), right-sided gray matter
heterotopia (Figure 1D), and bilateral periventricular cysts
(not shown). He had a persistently elevated blood lactate
(2.9–6.2mmol/L, ref < 2.0mmol/L) and an elevated
lactate/pyruvate ratio (22, ref 10–20), but all other labora-
tory results were normal, including urinary organic
acids, plasma organic acids, creatine kinase, serum
MMA, ammonia, free/total carnitines, and IGF1. By age
3, his dysphagia had progressed so that feeding was taking
an unfeasibly long time and, as a result, he began to
lose weight. He was admitted age 3 years, 2 months
for increasing lethargy and pneumonia, but he deterio-
rated further, developing respiratory failure that re-
quired intubation, tracheostomy, and a gastrostomy tube.
Despite these efforts, subject 2 died at the age of 4 years,
1 month.
Subject 3 was the second child of healthy, non-consan-
guineous German parents; his older sister is healthy. Hisrican Journal of Human Genetics 106, 92–101, January 2, 2020 93
Figure 1. Neuroimaging of Subjects Har-
bouring Bi-Allelic PathogenicNDUFAF8Var-
iants
(A and B) Subject 1 at 5 months of age.
(C and D) Subject 2 at 2 years, 9 months of
age.
(E and F) Subject 3 at 1 year, 2 months of
age.
Sagittal T1-weighted imaging (T1WI) (A, C,
and E) demonstrates dysmorphic corpus cal-
losum (arrows): For subjects 1 and 2, no
splenium is present (A and C), and only a
small posterior part of the splenium is pre-
sent in subject 3 (E). Sagittal T1WI (C and
E) reveals signal abnormality in the dorsal
brainstem corresponding to areas with
restricted diffusion for subjects 2 and 3. Cor-
onal T2-weighted imaging (B) of subject 1
demonstrates bilateral periventricular cysts
and absent septum pellucidum (arrows).
Axial T2-weighted imaging (D) depicts right
frontal gray matter heterotopia in subject 2
(arrow). Axial diffusion-weighted imaging
(F) shows bilateral symmetrical diffusion re-
striction in the putamina, thalami, and hip-
pocampal tails in subject 3 (arrows).gestation, delivery, and neonatal phase were all unremark-
able, and development was age-appropriate until the age
of 15 months. He was mainly breastfed, and his parents
reported he lacked drive to wean onto solid foods. At
age 15 months, he presented with severe dehydration
precipitated by two days of fever, vomiting, and diarrhea.
At this time, his weight was 9.8 kg (30th centile) and
height was 84 cm (95th centile). He was first admitted
at 1 year, 2 months of age in hypertensive crisis; brain
MRI (Figure 1) obtained at this time depicted bilateral sym-
metrical signal abnormality in the dorsal brainstem94 The American Journal of Human Genetics 106, 92–101, January 2, 2020(Figure 1E), basal ganglia, thalamus,
and hippocampi (Figure 1F) and corpus
callosum dysgenesis (Figure 1E). Labo-
ratory investigations reported meta-
bolic acidosis (pH 7.24, pCO2
28.2 mmHg, HCO3 12.2 mmol/L, BE
13.8 mmol/L) with normal blood
lactate 1.44 mmol/L (ref < 2mmol/L)
and slightly elevated cerebrospinal
fluid (CSF) lactate (3mmol/L, ref <
2.1mmol/L). Urinary organic acids
demonstrated an increased concentra-
tion of Krebs cycle intermediates. He
also had normochromic, normocytic
anemia (Hb 7.9 mg/dl, MCV 80 fl,
MCH 25.9 pg, MCHC 32.4 g/dl), fo-
linic acid deficiency (1.4 ng/mL, ref >
12.2), and vitamin B12 deficiency
(125 pg/mL, ref 400-883). One week af-
ter admission, he presented with
inconsolable crying and in hyperten-
sive crisis which was difficult to treat.He was discharged following gastrostomy (PEG) tube inser-
tion on account of failure to thrive and feeding problems.
He died during another hypertensive crisis at the age of
18 months.
Informed consent for diagnostic and research studies
was obtained for all subjects in accordance with the
Declaration of Helsinki protocols and approved by local
institutional review boards. Muscle biopsy was per-
formed for subjects 1 and 3 due to clinical suspicion
of a mitochondrial disorder. Routine histochemical in-
vestigations including sequential cytochrome c oxidase
(COX)/succinate dehydrogenase (SDH) histochemistry
and modified Gomori trichrome staining were unremark-
able, with no COX-deficient fibers reported in either
case. Spectrophotometric analysis of mitochondrial-
enriched muscle homogenates (subjects 1 and 3) and
skin fibroblasts (subject 1), were performed as previously
described.13 Results supported a marked isolated complex
I deficiency in the muscle (Figure 2A) and fibroblasts
(Figure 2B) from subject 1, with complex I activity
measured at 33% activity in muscle, and 47% in
fibroblasts, relative to citrate synthase. Analysis of muscle
biopsy from subject 3 revealed a residual complex I
activity of just 3% (expressed relative to citrate synthase
activity), although additional tissue was not available
for further study. Quadruple immunofluorescent histo-
chemistry14 supported an isolated complex I deficiency
for subject 1 (Figure 2C). No muscle biopsy was available
from subject 2 as a molecular diagnosis was sought at
an early stage in the diagnostic pipeline. Molecular
genetic investigations were initiated for all three
subjects through the use of ethylenediaminetetraacetic
acid (EDTA) blood DNA samples. A bespoke targeted
strategy was employed for subject 1; in brief, a supple-
mental panel of short (200bp) amplicons corresponding
to the coding exons (þ/ 10bp at the intron boundaries)
of NDUFAF8 were spiked into an existing custom
‘‘complex I’’ ampliseq library for IonTorrent PGM
sequencing. Library preparation, PGM sequencing, and
bioinformatic analysis were performed essentially as re-
ported.15 Whole-exome sequencing was performed for
subjects 2 and 3 through the use of previously reported
methodologies and interpreted according to American
College of Medical Genetics (ACMG) guidelines.11,16,17
Analysis of the genetic data revealed candidate patho-
genic variants in NDUFAF8 (RefSeq: NM_001086521.1)
for all three subjects (Figure 2D). Subjects 1 and 2 were
each observed to have a single heterozygous class 5
ACMG variant, a c.45_52dup (p.Phe18Serfs*32) duplica-
tion in subject 1 and a c.1A>G (p.?) variant in subject
2. Subject 3 was found to harbor an unreported homozy-
gous c.165C>G (p.Phe55Leu) variant; amino acid Phe55
is invariant across Boreoeutheria to at least Danio rerio, so
this finding supports potential functional importance
(Figure S1). Given that the clinical presentations of sub-
jects 1 and 2 were compatible with a complex I disorder,
the presence of a single heterozygous pathogenic NDU-
FAF8 variant in each subject prompted further investiga-
tion to determine whether additional undetected patho-
genic variants were present in NDUFAF8.
The gene structure of NDUFAF8 facilitated additional
genetic investigations—the cDNA is just 225 base pairs
across three exons that span 3 kb of genomic sequence
(Figure S2). WES data for subject 2 included sufficient reads
that mapped to the introns of NDUFAF8 to enable detec-
tion of a heterozygous intronic variant, c.195þ271C>T.
In contrast, the sequencing strategy utilized for subject 1
resulted in minimal intronic sequence reads, necessitatingThe Amefurther experimentation. A long-range PCR amplicon
spanning the entire NDUFAF8 locus was prepared for
Ion Torrent PGM sequencing through the use of the Ion
Xpress Plus Fragment Library Kit (Life Technologies) ac-
cording to the manufacturer’s protocol. Analysis of the
resultant sequence data revealed an identical heterozygous
intronic c.195þ271C>T variant in subject 1 (Figure 2E).
The identified NDUFAF8 variants reported here have
been submitted to the ClinVar database (see Accession
Numbers). To investigate whether the c.195þ271C>T
variant was associated with an mRNA defect, a fibroblast
cell line from subject 1 was referred for cDNA sequence
analysis. Whole RNA was extracted from subject and con-
trol fibroblasts and reverse transcribed as previously re-
ported.18 Analysis was performed on confluent fibroblasts
grown under either standard tissue culture conditions
using Dulbecco modified eagle medium (DMEM) or with
an additional overnight culture in emetine-containing
media (100mg/mL) to preserve any mRNA transcripts
that would normally be subject to nonsense-mediated
mRNA decay.19 Sequencing analysis of PCR-amplified
NDUFAF8 transcripts supported the loss of the NDUFAF8
allele that harbored the intronic c.195þ271C>T variant,
demonstrated by a loss of heterozygosity at the c.45_52
duplication locus (Figure 2F). PCR amplification and
electrophoresis of the NDUFAF8 transcripts through a 2%
agarose gel facilitated identification of normal- and
abnormal-length cDNA fragments (Figure S3). Amplicons
from subject 1 and a healthy control were excised by crude
band-stab, PCR-amplified, and subjected to Sanger
sequencing; the results supported the likelihood of a loss
of the functionally relevant transcript (isoform 2) in sub-
ject 1 fibroblast-derived cDNA, with only the non-func-
tional isoform 3 transcript detectable.
Availability of muscle biopsy and a fibroblast cell line
from subject 1 facilitated further characterization of his
identified NDUFAF8 variants. To investigate the oxidative
capacity of his fibroblasts, high-resolution respirometry
analysis of subject 1 and control fibroblasts was performed
using the Oxygraph-2k platform and DatLab software
v6.1.0.7, as described elsewhere.20 Respirometry demon-
strates a reduction in oxidative capacity in the fibroblasts
from subject 1 relative to controls (Figure S4). Blue-Native
(BN)-PAGE of enriched mitochondrial fractions from
muscle (Figure 3A) and fibroblasts (Figure 3B) of subject 1
and controls was performed as previously reported.21
Immunoblotting using antibodies raised against structural
subunits from each OXPHOS complex (complex I
[NDUFB8], complex II [SDH70], complex III [core 2], com-
plex IV [COXI], and complex V [ATP5A]) revealed
decreased levels of fully assembled complex I in both
muscle cells and fibroblasts from subject 1 when compared
to controls. All other OXPHOS complexes were unaffected,
thus corroborating the hypothesis of involvement of
subject 1’s NDUFAF8 variants in his pathology.
In light of the marked complex I defect in the fibroblast
cell line from subject 1, lentiviral rescue of the biochemicalrican Journal of Human Genetics 106, 92–101, January 2, 2020 95
Figure 2. Bi-Allelic NDUFAF8 Variants Are
Identified in Three Unrelated Subjects
Respiratory chain enzyme analysis reveals a
marked isolated complex I deficiency in
subject 1’s skeletal muscle biopsy (shaded
blue) compared to controls (shaded red)
(A); this finding is recapitulated in the fibro-
blasts from subject 1 (B). Mean enzyme ac-
tivities of muscle controls (n ¼ 25) and
fibroblast controls (n ¼ 10) are set to
100%, with error bars representing standard
deviation. The asterisk denotes a significant
loss of enzyme activity.
(C) Quadruple immunofluorescent histo-
chemical analysis of skeletal muscle biopsy
from subject 1 demonstrates reduced levels
of NDUFB8 (complex I) in the majority of
single muscle fibers relative to those of the
marker protein (porin), and expression of
COX1 (complex IV) is preserved. Each dot
represents a single muscle fiber. Black
dashed lines represent the SD limits for the
classification of the fibers. The X- and
Y-axes represent the expression of NDUFB8
and COX-1: normal (< 1), intermediate
þve (1 to 2 SD), intermediate ve (2
to 3 SD), and deficient (> 3 SD). The
mean expression level of normal fibers is de-
noted a value of 0. Dots that fall outwith the
solid box at -3 SD are strongly deficient fi-
bres. Dots are color coded according to their
mitochondrial mass (very low, blue; normal,
beige; very high, red).
(D) Family pedigrees of subjects 1, 2, and 3 and corresponding recessive NDUFAF8 variants; compound heterozygous c.45_52dup
(p.Phe18Serfs*32) and c.195þ271C>T (p.?) NDUFAF8 variants in subject 1; compound heterozygous c.1A>G (p.?) and
c.195þ271C>T (p.?) NDUFAF8 variants in subject 2 and a homozygous c.165C>G (p.Phe55Leu) NDUFAF8 variant in subject 3.
(E) Sequencing chromatograms depict the c.45_52dup and c.195þ271C>T variants present in genomic DNA from S1.
(F) cDNA studies using RNA derived from subject 1 fibroblasts show that only the c.45_52dup allele is present at the mRNA level, sup-
porting the possibility of degradation of the transcript associated with the c.195þ271C > T variant.
S1 ¼ subject 1; C ¼ wild-type control. Variant nomenclature is according to GenBank accession NM_001086521.1phenotype was attempted through reintroduction of a
wild-type version of NDUFAF8. In brief, we generated a
modified third-generation lentiviral construct that con-
tained an EF1a promoter;22,23 the vector details are avail-
able on the Addgene database (see Web Resources).
Cultured fibroblasts from subject 1 were infected with
either a FLAG-tagged NDUFAF8-encoding lentivirus or
an empty vector in order to generate two polyclonal cell
lines: one line expressing NDUFAF8-FLAG (þAF8), and its
empty vector counterpart (–AF8) that served as a negative
control for off-target effects. NDUFAF8-FLAG production
in the þAF8 cell line was confirmed by immunoblot
(Figure S5). To determine whether a rescue was obtained
following transduction with wild-type NDUFAF8-FLAG
cDNA, BN-PAGE was performed on mitochondria-en-
riched fractions using the –AF8 andþAF8 lines (Figure 3C).
The results confirmed a substantial increase in fully
assembled Complex I in the subject fibroblasts express-
ing NDUFAF8-FLAG, supporting the likelihood of a
rescue of the complex I assembly defect for subject
1, with little effect on the assembly of the other
complexes. In light of the previous association between
NDUFAF5 and NDUFAF8, NDUFAF5 steady-state levels96 The American Journal of Human Genetics 106, 92–101, January 2,were assayed by SDS-PAGE of cell lysates (Figure 3D).
Immunoblotting with an antibody raised against NDU-
FAF5 (Abcam ab192235) confirmed a loss of NDUFAF5
in subject 1’s primary cell line (S1p) and the subject
line transduced with the empty vector (-AF8), a result
consistent with previous investigations12 and supporting
the likelihood of an association between NDUFAF5 and
NDUFAF8 in mammalian cells. These data are further
corroborated by the marked increase in the steady-state
level of NDUFAF5 in subject 1’s NDUFAF8þ transduced
line (þAF8). Porin (Abcam ab14734) was used as a
loading control. Finally, spectrophotometric analysis of
the þAF8 and -AF8 lines was undertaken, demonstrating
a marked increase in complex I activity in subject 1’s
NDUFAF8þ transduced line (þAF8); the empty vector
(-AF8) cell line showed no measurable rescue when a
colorimetric complex I activity assay (ab109721, Life
Technologies) was used (Figure 3E). Data using the color-
imetric assay (ab109721, Life Technologies), which dem-
onstrates the complex I deficiency in subject 1 fibro-
blasts, are shown in Figure S6. Together, these data
demonstrate that overexpression of NDUFAF8 is suffi-
cient to rescue complex I assembly, NDUFAF5 levels,2020
Figure 3. BN-PAGE and Complementa-
tion Studies
(A and B) Mitochondria isolated from
cultured skin fibroblasts (A) and skeletal
muscle (B) from subject 1 and age-matched
control subjects were solubilized in n-do-
decyl b-d-maltoside (DDM) and subjected
to BN-PAGE and immunoblotting analysis
using antibodies directed to various OX-
PHOS complexes (complex I: NDUFB8;
complex II: SDHA; complex III: Core2; com-
plex IV: COX1; complex V: ATP5A). A strik-
ing reduction in assembled complex I was
apparent in both the skeletal muscle biopsy
and fibroblast cell line from subject 1 in
comparison to controls. C, Wild-type NDU-
FAF8 cDNA was generated and introduced
into control and subject cell lines via lenti-
viral expression under the EF1a promoter.
Enriched mitochondria were solubilized in
DDM before BN-PAGE analysis. Immunoblotting using antibodies against the complex I subunit NDUFA9 (top) and the complex II sub-
unit SDHA (bottom) as a loading control revealed less complex I in subject cell lines than in control cell lines. After transduction with
NDUFAF8 cDNA, complex I levels were restored. D, SDS-PAGE and western blotting of whole fibroblast cell lysates from subject 1 trans-
duced with wild-type NDUFAF8 cDNA (þFAF8) clearly demonstrates increased levels of NDUFAF5 relative to the empty vector (-FAF8) or
untreated subject 1 fibroblasts (S1p), comparable to those observed in the healthy agematched control, C. E, Comparison of the complex
1 activity exhibited by subject 1 fibroblasts following transduction with either the empty vector (–FAF8) or wild-type NDUFAF8mRNA
vector (þFAF8) cell lines corroborates functional rescue of the biochemical phenotype. Experimental data shown are derived from the
results of three technical replicate assays; error bars are at 1 standard deviation. P value calculated as by Student’s t test.and complex I activity in the fibroblast cell line from
subject 1.
A deeper understanding of the impact of subject 1’s
NDUFAF8 variants on respiratory chain complex assembly
and the steady-state levels of other mitochondrial proteins
was achieved using complexome profiling, a quantitative
mass-spectroscopy assay that has previously been informa-
tive in the initial characterization of other complex I
genes.24,25 Enriched mitochondrial fractions from subject
1 and control fibroblast cell lines were subjected to BN-
PAGE, systematic dissection of the polyacrylamide gel,
tryptic digestion, and mass spectroscopy (MS) essentially
as reported previously.25,26 MS data, protein identification,
quantification, and complete interaction profiles of mito-
chondrial membranes from subject 1 and control fibro-
blasts together with methodical details were deposited to
the ProteomeXchange Consortium27 via the PRIDE part-
ner repository with the dataset identifier PXD015749.
Protein abundance in each discrete section of the BN-
PAGE gel was transformed for representation as a heatmap
(Figure 4). These data show a generalized reduction in
complex I subunits in subject 1 fibroblasts (Figure 4B) rela-
tive to healthy control fibroblasts (Figure 4A); this result is
consistent with the results of initial BN-PAGE analyses. A
clear reduction in the assembled respirasome (CI-III2-IV)
is apparent in subject 1 fibroblasts (Figure 4B, purple
box), with a concomitant increase in ‘‘free’’ complex III
(Figure 4B, gray box). The current model of complex I
(CI) assembly involves multiple pathways that converge
to form the final mature CI. The Q module nucleates
assembly of the PP-a and PP-b modules, while the N, PD-a
and PD-b modules assemble separately. These modules
then join to form the complex I holoenzyme.28,29 GivenThe Amethat NDUFAF8 is required for NDUFAF5’s stability, we
expect subject 1 to experience the same complex I assem-
bly defects found in subjects with NDUFAF5 mutations,
namely defects in Q module assembly.30 Indeed, absence
of NDUFAF8 results in a stalled Q module assembly
involving at least three of the Q module subunits
(NDUFS2, NDUFS3, and NDUFA5) (Figure 4B, orange
box). Stalling at this early assembly stage results in
increased turnover of the later modules, as reflected in
decreased levels of CI subunits. The defect in Q module as-
sembly also appears to cause stalling of the PD-a module as-
sembly (Figure 4B, blue box), as well as decreased levels of
the PD-b module, summarized in the accompanying sche-
matic (Figure 4C).
NDUFAF8 harbors a twin Cx9C motif; therefore it is
classified as a member of the Cx9C protein family. Most of
these proteins exist in the mitochondrial intermembrane
space (IMS), including three IMS-facing subunits of com-
plex I (NDUFS5, NDUFB7, and NDUFA8) and one IMS-
facing subunit of complex IV (COX6B).31 The CHCHD4/
ALR (Mia40/Erv1 in yeast) system oxidises the disulfide
bonds to create a hairpin-like structure in the IMS. In yeast,
the mitochondrial ribosome protein Mrp10p is known
to be reduced by this system before import into the ma-
trix.32 While it has not been experimentally proven
whether NDUFAF8 localizes to the IMS33 or matrix,34 we
presume co-localization of NDUFAF8 to the matrix by
virtue of its association with NDUFAF5.12,30,34
Subjects 1 and 2 both harbor bi-allelic null mutations
that are predicted to abolish the NDUFAF8 protein,
but subject 3 was found to harbor a homozygous
missense variant. The c.165C>G (p.Phe55Leu) substitu-
tion involves an invariant amino acid, suggestive ofrican Journal of Human Genetics 106, 92–101, January 2, 2020 97
Figure 4. Complexome Profiling of Fibroblasts from Subject 1 Confirms Complex I Assembly Defect
Enriched mitochondrial membranes derived from control (A) and subject 1 (B) fibroblasts were solubilized with digitonin, separated on
native gradient gels, cut into 60 pieces and digested with trypsin. Peptides were analyzed by quantitative mass spectrometry. Intensity-
based absolute quantification (IBAQ) values of subject set were normalized to the sum of all values from control dataset. For visualization
in a heatmap, values were normalized to maximum appearance between both samples. There is a reduction in the functional respira-
some (complex I/III2/IV) (purple box) in subject fibroblasts and stalled assembly intermediates corresponding to PD-a (blue box) and a
partly-assembled Q module (orange box), compared to control fibroblast data. There is also an increase in ‘‘free’’ complex III (gray
box). Complex I subunits are presented according to their ascribed module, N-module (N), Q-module (Q), proximal P-module (PP-a con-
taining ND1, PP-b containing ND2/3/6), distal P-module (PD-a containing ND4, PD-b containing ND5) and assembly factors (A). Color-
matched dashed boxes are used to denote the corresponding regions of interest in the control data (Panel A). Subcomplex denotations
are according to Guerrero-Castillo and colleagues28 C. Complexome data schematic summarizes the consequence of defective NDUFAF8
on complex I assembly. Complex I subcomplexes are color-coded and named consistent with Panels A and B.functional importance, but without additional tissue for
functional validation, we can only speculate on the
mechanism of pathogenicity. The Phe55 residue is situ-
ated within a helical domain that forms one side of the
predicted hairpin structure of NDUFAF8 (Figure S1A).
Based upon TRIAP1, another member of the Cx9C family,
the Phe55 residue is predicted to be critical for protein-
protein interaction35 (Figure S1B), and it could represent
a key residue for the interaction between NDUFAF5
and NDUFAF8.32 The Phe55 residue could also be critical
for protein stability; this possibility is exemplified by a
pathogenic variant involving another member of the
Cx9C family, COA6, in which a pathogenic mutation
involving the conserved aromatic Trp59 residue was
shown to cause COA6 protein instability.36 A screen of98 The American Journal of Human Genetics 106, 92–101, January 2,variants reported in GnomAD shows that non-synony-
mous variation involving NDUFAF8 is rare, particularly
involving the conserved aromatic residues; given the
small size of NDUFAF8 (74aa, RefSeq: NP_001079990.1),
the prevalence of sequence variants was undertaken
for all aromatic residues—Trp8, Phe18, Tyr32, Phe50,
Phe55, and Phe62. In fact, there are no non-synonymous
variants affecting the Trp8, Phe18, Tyr32 or Phe62 resi-
dues according to gnomAD v2.1.37 Only one heterozy-
gous variant is recorded for the Phe50 and Phe55 residues
-c.150C>A p.Phe50Leu (MAF ¼ 3.18x105; 1/31392 al-
leles) and c.164T>C p.Phe55Ser (MAF ¼ 7.46x106, 1/
134102 alleles). Although the precise function of NDU-
FAF8 remains to be elucidated, it is clear that its aromatic
residues must be fundamentally important, and this is2020
consistent with subject 30s rapidly progressive disease
course.
It is interesting that subjects 1 and 2 were both reported
to have optic nerve involvement, with optic atrophy
and a small optic nerve, respectively. Optic atrophy
and/or neuropathy is often the predominant feature
associated with either OPA1mutations or Leber Hereditary
Optic Neuropathy (LHON, MIM: 500001), and this is often
due to one of three mtDNA point mutations. Each
common LHON mutation affects a complex I subunit,
m.3460G>A, p.Ala52Thr (ND1); m.11778G>A, p.Ar-
g340His (ND4); or m.14484T>C, p.Met64Val (ND6) (all
variants refer to RefSeq: NC_012920.1). Affected individ-
uals typically present in adulthood, although early onset
has been reported.38 Recessive pathogenic mutations
involving NDUFAF539 have also been reported in affected
individuals with prominent optic nerve involvement. It
is widely accepted that the optic nerve is particularly
susceptible to complex I dysfunction,40 but the link be-
tween genotype and phenotype—like many aspects of
mitochondrial pathology—remains to be elucidated.
In summary, we describe three young boys whose his-
tories, examinations, and cranial MRI findings supported
a clinical diagnosis of Leigh syndrome and who were sub-
sequently found to harbor bi-allelic pathogenic variants in
NDUFAF8, which encodes a recently identified mitochon-
drial complex I assembly factor. Through lentiviral rescue
of the biochemical complex I deficiency, we unequivocally
demonstrate that defective NDUFAF8 is the cause of dis-
ease in the subject for whom biological tissues were avail-
able. The presence of a recurrent intronic variant in two
subjects highlights the importance of thorough interroga-
tion of available intronic sequence data, particularly in
cases where a single heterozygous ACMG class 5 variant
has been identified. We would recommend that when tar-
geted genetic analysis is undertaken, either by capture or
selective analysis of unbiased NGS datasets, sequencing
analysis of NDUFAF8 should be undertaken for children
with suspected mitochondrial disease, particularly those
with optic involvement and/or Leigh syndrome.Accession Numbers
The accession numbers for variants NM_001086521.1:c.1A>G,
c.45_52dup, c.195þ271C>T, and c.165C>G are ClinVar:
SCV000995081, SCV000995082, SCV000995083 and
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Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.12.001.Acknowledgments
The authors would like to thank the families who participated in
this study. Work in our laboratories is supported by the Wellcome
Centre for Mitochondrial Research (203105/Z/16/Z), the MedicalThe AmeResearch Council (MRC) International Centre for Genomic Medi-
cine in Neuromuscular Disease, Newcastle University Centre for
Aging and Vitality (supported by the Biotechnology and Biological
Sciences Research Council and Medical Research Council
[G016354/1]), the National Institute of Health Research (NIHR)
Biomedical Research Centre in Age and Age RelatedDiseases award
to the Newcastle upon Tyne Hospitals National Health Service
(NHS) Foundation, the Medical Research Council (MRC) and
Engineering and Physical Sciences Research Council (ESPRC) New-
castle Molecular Pathology Node, the NHS Highly Specialised Ser-
vice for Rare Mitochondrial Disorders, the Lily Foundation, and
the National Institutes of Health (NIH) (R35GM131795 to
D.J.P.). C.L.A. is supported by the National Institute for Health
Research (NIHR) Post-Doctoral Fellowship (PDF-2018-11-ST2-
021). M.T.V. is supported by the National Science Foundation
(NSF) Graduate Research Fellowship (DGE-1256259). I.W. is sup-
ported by the Deutsche Forschungsgemeinschaft: SFB 815/Z1
from the Bundesministerium fu¨r Bildung und Forschung (BMBF)
mitoNET—German Network for Mitochondrial Disorders
(01GM1906D). H.P. is supported by the BMBF and Horizon2020
through E-Rare project GENOMIT (01GM1603) and the German
Network for Mitochondrial Disorders (mitoNET 01GM1906B).
P.E.B. is supported by the NIH National Institute of Neurological
Disorders and Stroke (R01NS083726). We thank Jana Meister-
knecht for excellent technical assistance in BN-PAGE and sample
preparation for complexome profiling. The views expressed in
this publication are those of the author(s) and not necessarily
those of the NHS, the NIHR, or the Department of Health and
Social Care.Declaration of Interests
The authors declare no competing interests.
Received: October 30, 2019
Accepted: December 2, 2019
Published: December 19, 2019Web Resources
Addgene, http://www.addgene.org/85132
AlignGVGD, http://agvgd.hci.utah.edu/agvgd_input.php
CADD, https://cadd.gs.washington.edu/
ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/
Ensembl, www.ensembl.org/
ExAC Browser, http://exac.broadinstitute.org/
GenBank, https://www.ncbi.nlm.nih.gov/genbank/
gnomAD, http://gnomad.broadinstitute.org/
OMIM, https://www.omim.org/
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/
SIFT, http://sift.bii.a-star.edu.sg/
UCSC Genome Browser, https://genome.ucsc.edu/
UniProt, https://www.uniprot.org/References
1. Rahman, S., Blok, R.B., Dahl, H.H., Danks, D.M., Kirby, D.M.,
Chow, C.W., Christodoulou, J., and Thorburn, D.R. (1996).
Leigh syndrome: clinical features and biochemical and DNA
abnormalities. Ann. Neurol. 39, 343–351.rican Journal of Human Genetics 106, 92–101, January 2, 2020 99
2. Li, T.R., Wang, Q., Liu, M.M., and Lv, R.J. (2019). A Chinese
Family With Adult-Onset Leigh-Like Syndrome Caused by
the Heteroplasmic m.10191T>C Mutation in the Mitochon-
drial MTND3 Gene. Front. Neurol. 10, 347.
3. Poole, O.V., Everett, C.M., Gandhi, S., Marino, S., Bugiardini,
E., Woodward, C., Lam, A., Quinlivan, R., Hanna, M.G., and
Pitceathly, R.D.S. (2019). Adult-onset Leigh syndrome linked
to the novel stop codon mutation m.6579G>A in MT-CO1.
Mitochondrion 47, 294–297.
4. Lake, N.J., Compton, A.G., Rahman, S., and Thorburn, D.R.
(2016). Leigh syndrome: One disorder, more than 75 mono-
genic causes. Ann. Neurol. 79, 190–203.
5. Tuppen, H.A., Hogan, V.E., He, L., Blakely, E.L., Worgan, L., Al-
Dosary, M., Saretzki, G., Alston, C.L., Morris, A.A., Clarke, M.,
et al. (2010). The p.M292T NDUFS2mutation causes complex
I-deficient Leigh syndrome in multiple families. Brain 133,
2952–2963.
6. Zhu, Z., Yao, J., Johns, T., Fu, K., De Bie, I., Macmillan, C.,
Cuthbert, A.P., Newbold, R.F., Wang, J., Chevrette, M., et al.
(1998). SURF1, encoding a factor involved in the biogenesis
of cytochrome c oxidase, is mutated in Leigh syndrome. Nat.
Genet. 20, 337–343.
7. Naito, E., Ito, M., Yokota, I., Saijo, T., Matsuda, J., Osaka, H.,
Kimura, S., and Kuroda, Y. (1997). Biochemical and molecular
analysis of an X-linked case of Leigh syndrome associatedwith
thiamin-responsive pyruvate dehydrogenase deficiency.
J. Inherit. Metab. Dis. 20, 539–548.
8. Tucker, E.J., Hershman, S.G., Ko¨hrer, C., Belcher-Timme, C.A.,
Patel, J., Goldberger, O.A., Christodoulou, J., Silberstein, J.M.,
McKenzie, M., Ryan, M.T., et al. (2011). Mutations in MTFMT
underlie a human disorder of formylation causing impaired
mitochondrial translation. Cell Metab. 14, 428–434.
9. Peters, H., Buck, N., Wanders, R., Ruiter, J., Waterham, H., Kos-
ter, J., Yaplito-Lee, J., Ferdinandusse, S., and Pitt, J. (2014).
ECHS1mutations in Leigh disease: a new inborn error of meta-
bolism affecting valine metabolism. Brain 137, 2903–2908.
10. Josephs, K.S., Berner, A., George, A., Scott, R.H., Firth, H.V.,
Tatton-Brown, K.; and Health Education England’s Genomic
Education Programme (2019). Genomics: the power, potential
and pitfalls of the new technologies and how they are trans-
forming healthcare. Clin. Med. (Lond.) 19, 269–272.
11. Kremer, L.S., Bader, D.M., Mertes, C., Kopajtich, R., Pichler, G.,
Iuso, A., Haack, T.B., Graf, E., Schwarzmayr, T., Terrile, C., et al.
(2017). Genetic diagnosis of Mendelian disorders via RNA
sequencing. Nat. Commun. 8, 15824.
12. Floyd, B.J., Wilkerson, E.M., Veling, M.T., Minogue, C.E., Xia,
C., Beebe, E.T., Wrobel, R.L., Cho, H., Kremer, L.S., Alston,
C.L., et al. (2016). Mitochondrial Protein InteractionMapping
Identifies Regulators of Respiratory Chain Function. Mol. Cell
63, 621–632.
13. Kirby, D.M., Thorburn, D.R., Turnbull, D.M., and Taylor, R.W.
(2007). Biochemical assays of respiratory chain complex activ-
ity. Methods Cell Biol. 80, 93–119.
14. Ahmed, S.T., Alston, C.L., Hopton, S., He, L., Hargreaves, I.P.,
Falkous, G., Ola´hova´, M., McFarland, R., Turnbull, D.M., Ro-
cha, M.C., and Taylor, R.W. (2017). Using a quantitative
quadruple immunofluorescent assay to diagnose isolated
mitochondrial Complex I deficiency. Sci. Rep. 7, 15676.
15. Alston, C.L., Howard, C., Ola´hova´, M., Hardy, S.A., He, L.,
Murray, P.G., O’Sullivan, S., Doherty, G., Shield, J.P., Har-
greaves, I.P., et al. (2016). A recurrent mitochondrial
p.Trp22Arg NDUFB3 variant causes a distinctive facial appear-100 The American Journal of Human Genetics 106, 92–101, January 2ance, short stature and amild biochemical and clinical pheno-
type. J. Med. Genet. 53, 634–641.
16. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster,
J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al.; ACMG
Laboratory Quality Assurance Committee (2015). Standards
and guidelines for the interpretation of sequence variants: a
joint consensus recommendation of the American College
of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet. Med. 17, 405–424.
17. Yang, Y., Muzny, D.M., Reid, J.G., Bainbridge, M.N., Willis, A.,
Ward, P.A., Braxton, A., Beuten, J., Xia, F., Niu, Z., et al. (2013).
Clinical whole-exome sequencing for the diagnosis of mende-
lian disorders. N. Engl. J. Med. 369, 1502–1511.
18. Lax, N.Z., Alston, C.L., Schon, K., Park, S.M., Krishnakumar,
D., He, L., Falkous, G., Ogilvy-Stuart, A., Lees, C., King, R.H.,
et al. (2015). Neuropathologic Characterization of Pontocere-
bellar Hypoplasia Type 6 Associated With Cardiomyopathy
and Hydrops Fetalis and Severe Multisystem Respiratory
Chain Deficiency due to Novel RARS2 Mutations.
J. Neuropathol. Exp. Neurol. 74, 688–703.
19. Noensie, E.N., and Dietz, H.C. (2001). A strategy for disease
gene identification through nonsense-mediated mRNA decay
inhibition. Nat. Biotechnol. 19, 434–439.
20. Wu¨st, S., Dro¨se, S., Heidler, J., Wittig, I., Klockner, I., Franko,
A., Bonke, E., Gu¨nther, S., Ga¨rtner, U., Boettger, T., and Braun,
T. (2018). Metabolic Maturation during Muscle Stem Cell Dif-
ferentiation Is Achieved by miR-1/133a-Mediated Inhibition
of the Dlk1-Dio3 Mega Gene Cluster. Cell Metab. 27, 1026–
1039.e6.
21. Ola´hova´, M., Hardy, S.A., Hall, J., Yarham, J.W., Haack, T.B.,
Wilson, W.C., Alston, C.L., He, L., Aznauryan, E., Brown,
R.M., et al. (2015). LRPPRCmutations cause early-onset multi-
systemmitochondrial disease outside of the French-Canadian
population. Brain 138, 3503–3519.
22. Hayer, A., Shao, L., Chung, M., Joubert, L.M., Yang, H.W., Tsai,
F.C., Bisaria, A., Betzig, E., and Meyer, T. (2016). Engulfed cad-
herin fingers are polarized junctional structures between
collectively migrating endothelial cells. Nat. Cell Biol. 18,
1311–1323.
23. Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M.,
Trono, D., and Naldini, L. (1998). A third-generation lenti-
virus vector with a conditional packaging system. J. Virol.
72, 8463–8471.
24. Alston, C.L., Heidler, J., Dibley, M.G., Kremer, L.S., Taylor, L.S.,
Fratter, C., French, C.E., Glasgow, R.I.C., Feichtinger, R.G., De-
lon, I., et al. (2018). Bi-allelic Mutations in NDUFA6 Establish
Its Role in Early-Onset IsolatedMitochondrial Complex I Defi-
ciency. Am. J. Hum. Genet. 103, 592–601.
25. Heide, H., Bleier, L., Steger, M., Ackermann, J., Dro¨se, S.,
Schwamb, B., Zo¨rnig, M., Reichert, A.S., Koch, I., Wittig, I.,
and Brandt, U. (2012). Complexome profiling identifies
TMEM126B as a component of the mitochondrial complex I
assembly complex. Cell Metab. 16, 538–549.
26. Fuhrmann, D.C., Wittig, I., Dro¨se, S., Schmid, T., Dehne, N.,
and Bru¨ne, B. (2018). Degradation of the mitochondrial com-
plex I assembly factor TMEM126B under chronic hypoxia.
Cell. Mol. Life Sci. 75, 3051–3067.
27. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., He-
wapathirana, S., Kundu, D.J., Inuganti, A., Griss, J., Mayer,
G., Eisenacher, M., et al. (2019). The PRIDE database and
related tools and resources in 2019: improving support for
quantification data. Nucleic Acids Res. 47 (D1), D442–D450., 2020
28. Guerrero-Castillo, S., Baertling, F., Kownatzki, D., Wessels,
H.J., Arnold, S., Brandt, U., and Nijtmans, L. (2017). The As-
sembly Pathway of Mitochondrial Respiratory Chain Com-
plex I. Cell Metab. 25, 128–139.
29. Formosa, L.E., Dibley, M.G., Stroud, D.A., and Ryan, M.T.
(2018). Building a complex complex: Assembly of mitochon-
drial respiratory chain complex I. Semin. Cell Dev. Biol. 76,
154–162.
30. Sugiana, C., Pagliarini, D.J., McKenzie, M., Kirby, D.M., Salemi,
R., Abu-Amero, K.K., Dahl, H.H., Hutchison, W.M., Vascotto,
K.A., Smith, S.M., et al. (2008). Mutation of C20orf7 disrupts
complex I assembly and causes lethal neonatal mitochondrial
disease. Am. J. Hum. Genet. 83, 468–478.
31. Cavallaro, G. (2010). Genome-wide analysis of eukaryotic
twin CX9C proteins. Mol. Biosyst. 6, 2459–2470.
32. Modjtahedi, N., Tokatlidis, K., Dessen, P., and Kroemer, G.
(2016). Mitochondrial Proteins Containing Coiled-Coil-He-
lix-Coiled-Coil-Helix (CHCH)Domains in Health andDisease.
Trends Biochem. Sci. 41, 245–260.
33. Hung, V., Zou, P., Rhee, H.W., Udeshi, N.D., Cracan, V., Svin-
kina, T., Carr, S.A., Mootha, V.K., and Ting, A.Y. (2014). Prote-
omic mapping of the human mitochondrial intermembrane
space in live cells via ratiometric APEX tagging. Mol. Cell 55,
332–341.
34. Rhee, H.W., Zou, P., Udeshi, N.D., Martell, J.D., Mootha, V.K.,
Carr, S.A., and Ting, A.Y. (2013). Proteomic mapping of mito-
chondria in living cells via spatially restricted enzymatic
tagging. Science 339, 1328–1331.The Amer35. Miliara, X., Garnett, J.A., Tatsuta, T., Abid Ali, F., Baldie, H.,
Pe´rez-Dorado, I., Simpson, P., Yague, E., Langer, T., and Mat-
thews, S. (2015). Structural insight into the TRIAP1/PRELI-
like domain family of mitochondrial phospholipid transfer
complexes. EMBO Rep. 16, 824–835.
36. Stroud, D.A., Maher, M.J., Lindau, C., Vo¨gtle, F.N., Frazier,
A.E., Surgenor, E., Mountford, H., Singh, A.P., Bonas, M., Oel-
jeklaus, S., et al. (2015). COA6 is a mitochondrial complex IV
assembly factor critical for biogenesis of mtDNA-encoded
COX2. Hum. Mol. Genet. 24, 5404–5415.
37. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Al-
fo¨ldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A.,
Birnbaum, D.P., et al. (2019). Variation across 141,456 human
exomes and genomes reveals the spectrum of loss-of-function
intolerance across human protein-coding genes. bioRxiv,
531210.
38. Bosley, T.M., Brodsky, M.C., Glasier, C.M., and Abu-Amero,
K.K. (2008). Sporadic bilateral optic neuropathy in children:
the role of mitochondrial abnormalities. Invest. Ophthalmol.
Vis. Sci. 49, 5250–5256.
39. Simon, M.T., Eftekharian, S.S., Stover, A.E., Osborne, A.F.,
Braffman, B.H., Chang, R.C., Wang, R.Y., Steenari, M.R.,
Tang, S., Hwu, P.W., et al. (2019). Novel mutations in
the mitochondrial complex I assembly gene NDUFAF5
reveal heterogeneous phenotypes. Mol. Genet. Metab. 126,
53–63.
40. Wong-Riley, M.T. (2010). Energy metabolism of the visual sys-
tem. Eye Brain 2, 99–116.ican Journal of Human Genetics 106, 92–101, January 2, 2020 101
